|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
9
|
|
pubmed:dateCreated |
2007-10-25
|
|
pubmed:abstractText |
The tolerability and efficacy of the combination of tipifarnib, an orally bioavailable nonpeptidomimetic farnesyl transferase inhibitor, and imatinib was investigated in patients with chronic myelogenous leukemia in chronic phase who had failed imatinib.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Nov
|
|
pubmed:issn |
0008-543X
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
1
|
|
pubmed:volume |
110
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
2000-6
|
|
pubmed:meshHeading |
pubmed-meshheading:17849425-Adult,
pubmed-meshheading:17849425-Aged,
pubmed-meshheading:17849425-Aged, 80 and over,
pubmed-meshheading:17849425-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:17849425-Dose-Response Relationship, Drug,
pubmed-meshheading:17849425-Drug Resistance, Neoplasm,
pubmed-meshheading:17849425-Fusion Proteins, bcr-abl,
pubmed-meshheading:17849425-Humans,
pubmed-meshheading:17849425-Leukemia, Myelogenous, Chronic, BCR-ABL Positive,
pubmed-meshheading:17849425-Maximum Tolerated Dose,
pubmed-meshheading:17849425-Middle Aged,
pubmed-meshheading:17849425-Piperazines,
pubmed-meshheading:17849425-Pyrimidines,
pubmed-meshheading:17849425-Quinolones
|
|
pubmed:year |
2007
|
|
pubmed:articleTitle |
Phase 1 study of tipifarnib in combination with imatinib for patients with chronic myelogenous leukemia in chronic phase after imatinib failure.
|
|
pubmed:affiliation |
Department of Leukemia, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA. jcortes@mdahderson.org
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial, Phase I
|
